全部 标题 作者
关键词 摘要

PLOS ONE  2011 

Outer Membrane Protein A (OmpA) of Shigella flexneri 2a, Induces Protective Immune Response in a Mouse Model

DOI: 10.1371/journal.pone.0022663

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background In our earlier studies 34 kDa outer membrane protein (OMP) of Shigella flexneri 2a has been identified as an efficient immunostimulant. Key Results In the present study MALDI-TOF MS analysis of the purified 34 kDa OMP of Shigella flexneri 2a shows considerable sequence homology (Identity 65%) with the OmpA of S. flexneri 2a. By using the specific primers, the gene of interest has been amplified from S. flexneri 2a (N.Y-962/92) genomic DNA, cloned in pET100/D-TOPO? vector and expressed using induction with isopropyl thiogalactoside (IPTG) for the first time. Immunogenicity and protective efficacy of the recombinant OmpA has been evaluated in an intranasally immunized murine pulmonary model. The recombinant protein induces significantly enhanced protein specific IgG and IgA Abs in both mucosal and systemic compartments and IgA secreting cells in the systemic compartment (spleen). The mice immunized with OmpA have been protected completely from systemic challenge with a lethal dose of virulent S. flexneri 2a. Immunization with the protein causes mild polymorphonuclear neutrophil infiltration in the lung, without inducing the release of large amounts of proinflammatory cytokines. Conclusion These results suggest that the OmpA of S. flexneri 2a can be an efficacious mucosal immunogen inducing protective immune responses. Our findings also demonstrate that antibodies and Th1 immune response may be associated with the marked protective efficacy of immunized mice after intranasal shigellae infection.

References

[1]  Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swedlow DL, et al. (1999) Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 77: 651–666.
[2]  (2002) World Health Organization website updated on May 2002. Available: http://www.who.int/vaccines/en/shigella.?shtml. Accessed 2011 Jan,12.
[3]  Ashkenazi S, Levy I, Kazaronovsky V, Samra Z (2003) Growing antimicrobial resistance of Shigella isolates. J Antimicrob Chemother 51: 427–9.
[4]  Anders K, Li A, Zhao CR, Karlsson K, Minh NB, et al. (1995) Safety and immunogenicity of the auxotrophic Shigella flexneri 2a vaccine SFL1070 with a deleted aroD gene in adult Swedish volunteers. Vaccine 13: 88–9.
[5]  Coster TS, Charles HW, Lillian L, VanDeVerg A, Hartman AB, et al. (1999) Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 67: 3437–43.
[6]  Passwell JH, Harlev E, Ashkenazi S, Chu C, Miron D, et al. (2001) Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infect Immun 69(3): 1351–1357.
[7]  Ranallo RT, Fonseka CP, Cassels F, Srinivasan J, Venkatesan MM (2005) Construction and characterization of bivalent Shigella flexneri 2a vaccine strains SC608 (pCFAI) and SC608 (pCFAI/LTB) that express antigens from enterotoxigenic Escherichia coli. Infect Immun 73(1): 258–67.
[8]  Berry EM, Wang J, Wu T, Davis T, Levine MM (2006) Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model. Vaccine 24(18): 3728–34.
[9]  Turbyfill KR, Kaminski RW, Oaks EV (2008) Immunogenicity and efficacy of highly purified invasin complex vaccine from Shigella flexneri 2a. Vaccine 26(10): 1353–1364.
[10]  Kaminski RW, Turbyfill KR, Chao C, Ching WM, Oaks EV (2009) Mucosal adjuvanticity of a Shigella invasin complex with dna-based vaccines. Clin Vaccine Immunol 16(4): 574–586.
[11]  Kotloff KL, Noriega FR, Samandari T, Sztein MB, Losonsky GA, et al. (2000) Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infect Immun 68: 1034–1039.
[12]  Peng X, Ye X, Wang S (2004) Identification of novel immunogenic proteins of Shigella flexneri 2a by proteomic methodologies. Vaccine 2004; 22: 2750–2756.
[13]  Ying T, Wang H, Li M, Wang J, Shi Z, et al. (2005) Immunoproteomics of outer membrane proteins and extracellular proteins of Shigella flexneri 2a 2457T. Proteomics 5: 4777–4793.
[14]  Jennison AV, Raquib R, Verma NK (2006) Immunoproteomic analysis of soluble and membrane proteins of Shigella flexneri 2a 2457T. World J Gastroenterol 12(41): 6683–6688.
[15]  Mukhopadhaya A, Mahalanabis D, Khanam J, Chakrabarti MK (2003) Protective efficacy of oral immunization with heat-killed Shigella flexneri 2a in animal model: study of cross protection, immune response and antigenic recognition. Vaccine 21: 3043–50.
[16]  Mukhopadhaya A, Mahalanabis D, Chakrabarti MK (2006) Role of Shigella flexneri 2a 34 kDa outer membrane protein in induction of protective immune response. Vaccine 24: 6028–6036.
[17]  Pore D, Chowdhury P, Mahata N, Pal A, Yamasaki S, et al. (2009) Purification and characterization of an immunogenic outer membrane protein of Shigella flexneri 2a. Vaccine 27: 5855–5864.
[18]  Pore D, Mahata N, Pal A, Chakrabarti MK (2010) 34 kDa MOMP of Shigella flexneri promotes TLR2 mediated macrophage activation with the engagement of NF-κB and p38 MAP kinase signaling. Mol Immunol 47(9): 1739–1746.
[19]  Nikaido H, Nikaido K, Harayama S (1991) Identification and characterization of porins in Pseudomonas aeruginosa. J Biol Chem 266: 770–779.
[20]  Sharma AV, Sing J (2005) A nonenzymatic method to isolate genomic DNA from bacteria and actinomycete. Anal Biochem 337: 354–356.
[21]  Maniatis T, Fritsch F, Sambrook J (1982) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
[22]  Laemmli UK (1970) Change of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–5.
[23]  Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254.
[24]  Mallett CP, VanDeVerg L, Collins HH, Hale TL (1993) Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model. Vaccine 11: 190–196.
[25]  Grewal HMS, Karlsen TH, Vetvikn H, Ahren C, Gjessing HK, et al. (2000) Measurement of specific IgA in faecal extracts and intestinal lavage fluid for monitoring of mucosal immune responses. Journal of Immunological Methods 239: 53–62.
[26]  Kaminski RW, Turbyfill KR, Oaks EV (2006) Mucosal adjuvant properties of the Shigella invasin complex. Infect Immun 74: 2856–2866.
[27]  Ndungu FM, Cadman ET, Coulcher J, Nduati E, Couper E, et al. (2009) Functional memory B cells and long-lived plasma cells are generated after a single Plasmodium chabaudi infection in mice. PLoS Pathog 5(12): e1000690.
[28]  Brewer NR (1983) The mouse in biomedical research: normative biology, immunology, and husbandry. In: Foster HL, Small JD, Fox JG, editors. Respiratory physiology. New York: Academic Press, Inc.. 252 p. In.
[29]  Sonntag I, Schwarz H, Hirota Y, Henning U (1978) Cell envelope and shape of Escherichia coli: multiple mutants missing the outer membrane lipoprotein and other major outer membrane proteins. J Bacteriol 136: 280–285.
[30]  Belaaouaj AA, Kim KS, Shapiro SD (2000) Degradation of outer membrane protein A in Escherichia coli killing by neutrophil elastase. Science 289: 1185–1187.
[31]  Schweizer M, Henning U (1977) Action of a major outer cell envelope membrane protein in conjugation of Escherichia coli K-12. J Bacteriol 129: 1651–1652.
[32]  Shin S, Lu G, Cai M, Kim KS (2005) Escherichia coli outer membrane protein A adheres to human brain microvascular endothelial cells. Biochem Biophys Res Commun 330: 1199–1204.
[33]  Weiser JN, Gotschlich EC (1991) Outer membrane protein A (OmpA) contributes to serum resistance and pathogenicity of Escherichia coli K-1. Infect Immun 59: 2252.
[34]  Puohiniemi R, Karvonen M, Vuopio VJ, Muotiala A, Helander IM, et al. (1990) A strong antibody response to the periplasmic C-terminal domain of the OmpA protein of Escherichia coli is produced by immunization with purified OmpA or with whole E. coli or Salmonella typhimurium bacteria. Infect Immun 58: 1691–1696.
[35]  Soulas C, Baussant T, Aubry JP, Delneste Y, Barillat N, Caron G, et al. (2000) Outer membrane protein A (OmpA) binds to and activates human macrophages. J Immunol 165: 2335–2340.
[36]  Torres AG, Li Y, Tutt CB, Xin L, Eaves-Pyles T, et al. (2006) Outer membrane protein A of Escherichia coli O157:H7 stimulates dendritic cell activation. Infect Immun 74: 2676–2685.
[37]  Dumetz F, LaPatra SE, Duchaud E, Claverol S, Henaff ML (2007) The Flavobacterium psychrophilum OmpA, an outer membrane glycoprotein, induces a humoral response in rainbow trout. J Appl Microbiol 103: 1461–1470.
[38]  Koizumi N, Watanabe H (2003) Molecular cloning and characterization of a novel leptospiral lipoprotein with OmpA domain. FEMS Microbiol Lett 226: 215–219.
[39]  Crocquet-Valdes PA, Diaz-Montero CM, Feng HM (2001) Immunization with a portion of rickettsial outer membrane protein A stimulates protective immunity against spotted fever rickettsiosis. Vaccine 20: 979–988.
[40]  Li H, Xiong XP, Peng B, Xu CX, Ye MZ, et al. (2009) Identification of broad cross-protective immunogens using heterogeneous antiserum-based immunoproteomic approach. J Proteome Res 8: 4342–4349.
[41]  Mallett CP, Hale TL, Kaminski RW, Larsen T, Orr N, et al. (1995) Intranasal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection. Infect Immun 63(6): 2382–6.
[42]  Kurohane K, Kobayashi C, Imai Y (2005) Facilitated production of secretory IgA against Shiga toxin B subunits by intranasal application of antigen-coated polystyrene microspheres. Microbiol Immunol 49(2): 149–54.
[43]  Wijburg OL, Uren TK, Simpfendorfer K, Johansen FE, Brandtzaeg P, et al. (2006) Innate secretory antibodies protect against natural Salmonella typhimurium infection. J Exp Med 203(1): 21–6.
[44]  Singer M, Sansonetti PJ (2004) IL-8 is a key chemokine regulating neutrophil recruitment in a new mouse model of Shigella-induced colitis. J Immunol 173: 4197–4206.
[45]  Kobayashi SD, DeLeo FR (2009) Role of neutrophils in innate immunity: a systems biology-level approach. WIREs Syst Biol Med 1: 309–333.
[46]  Raqib R, Lindberg AA, Wretlind B, Bardhan PK, Andersson U, et al. (1995) Persistence of local cytokine production in shigellosis in acute and convalescent stages. Infect Immun 63: 289–296.
[47]  Raqib R, Wretlind B, Andersson J, Lindberg AA (1995) Cytokine secretion in acute shigellosis is correlated to disease activity and directed more to stool than to plasma. J Infect Dis 171: 376–384.
[48]  Bancroft GJ, Sheehan KCF, Schreiber RD, Unanue ER (1989) Tumor necrosis factor is involved in the T cell-independent pathway of macrophage activation in SCID mice. J Immunol 59: 1709–1715.
[49]  Jones SA (2005) Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 175: 3463–3468.
[50]  Niesel DW, Hess CB, Cho YJ, Klimpel KD, Klimpe GR (1986) Natural and recombinant interferons inhibit epithelial cell invasion by Shigella spp. Infect Immun 52: 828.

Full-Text

comments powered by Disqus